KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) EBIT Margin (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed EBIT Margin for 18 consecutive years, with 47.72% as the latest value for Q1 2026.

  • For Q1 2026, EBIT Margin rose 6387.0% year-over-year to 47.72%; the TTM value through Mar 2026 reached 39.84%, up 2603.0%, while the annual FY2025 figure was 8.45%, 5893.0% up from the prior year.
  • EBIT Margin hit 47.72% in Q1 2026 for Ionis Pharmaceuticals, up from 105.47% in the prior quarter.
  • Across five years, EBIT Margin topped out at 50.29% in Q2 2025 and bottomed at 136.95% in Q4 2022.
  • Average EBIT Margin over 5 years is 67.42%, with a median of 63.92% recorded in 2022.
  • Year-over-year, EBIT Margin crashed -50463bps in 2022 and then soared 13507bps in 2023.
  • Ionis Pharmaceuticals' EBIT Margin stood at 136.95% in 2022, then skyrocketed by 99bps to 1.89% in 2023, then crashed by -2493bps to 48.91% in 2024, then crashed by -116bps to 105.47% in 2025, then surged by 55bps to 47.72% in 2026.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 47.72%, 105.47%, and 102.21% for Q1 2026, Q4 2025, and Q3 2025 respectively.